ARCH Venture Management LLC Invests $129.35 Billion in Vir Biotechnology, Inc. $VIR

Key Points

• ARCH Venture Management acquired 12.7 million Vir Biotechnology shares in the second quarter, representing approximately 7.5% of the company and 11.8% of ARCH’s portfolio. Hedge funds and institutional investors collectively own 65.32% of Vir’s stock.
• Vir reported quarterly EPS of $0.47, exceeding the $0.33 consensus estimate, while revenue reached $238.95 million—up nearly 19,583% year over year and well above expectations.
• Shares recently traded at $10.71, up 8.1%, and analysts maintain a “Moderate Buy” consensus rating with an average price target of $20.62, despite one sell rating and continued projected full-year losses.

ARCH Venture Management LLC purchased a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,694,163 shares of the company's stock, valued at approximately $129,353,521,000. Vir Biotechnology accounts for 11.8% of ARCH Venture Management LLC's holdings, making the stock its 6th biggest position. ARCH Venture Management LLC owned approximately 7.50% of Vir Biotechnology as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock worth $41,000 after buying an additional 1,390 shares during the last quarter. CWM LLC lifted its position in shares of Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company's stock valued at $53,000 after buying an additional 1,646 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Vir Biotechnology by 7.8% during the 4th quarter. ProShare Advisors LLC now owns 23,525 shares of the company's stock worth $142,000 after acquiring an additional 1,705 shares during the period. Rhumbline Advisers grew its stake in shares of Vir Biotechnology by 1.0% during the 2nd quarter. Rhumbline Advisers now owns 228,949 shares of the company's stock worth $1,154,000 after acquiring an additional 2,300 shares during the period. Finally, Corient Private Wealth LLC grew its stake in shares of Vir Biotechnology by 1.0% during the 4th quarter. Corient Private Wealth LLC now owns 262,211 shares of the company's stock worth $1,572,000 after acquiring an additional 2,515 shares during the period. Hedge funds and other institutional investors own 65.32% of the company's stock.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the firm's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director owned 21,216 shares of the company's stock, valued at $200,491.20. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by corporate insiders.

Vir Biotechnology Trading Up 8.1%

Shares of NASDAQ:VIR opened at $10.71 on Wednesday. The company has a 50 day moving average of $9.48 and a 200 day moving average of $9.23. The stock has a market cap of $1.81 billion, a P/E ratio of -5.76 and a beta of 1.66. Vir Biotechnology, Inc. has a 12 month low of $4.36 and a 12 month high of $11.66.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.14. The business had revenue of $238.95 million for the quarter, compared to analysts' expectations of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The business's revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.80) EPS. On average, equities analysts forecast that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on VIR shares. Leerink Partners boosted their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an "outperform" rating in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a report on Thursday, August 6th. Finally, HC Wainwright restated a "buy" rating on shares of Vir Biotechnology in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $20.62.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source